Seminar in PM Week 9

Through a focus on efficiency in all of its procedures for releasing a new medicine, pharmaceutical companies have experienced advances in their portfolio management systems. A project's linkage with the organization's strategic business objectives was necessary for enhanced productivity, early identification of a medication profile, and testing to provide value to the R&D portfolios.

Project Purpose and Justification

The project aims to demonstrate how value-driven project and portfolio management can be used in pharmaceutical sector R&D departments to connect it with the company's strategic goals. Portfolio management will benefit the company by giving customers an effective productivity method for the new pharmaceuticals. This is accomplished by lowering risks and expenses, boosting market share and earnings, and, most importantly, raising organizational value. The pharmaceutical business has made significant expenditures in research and development throughout the years, and unlike any other institution, its primary goal is to turn a profit. The pharmaceutical industry, therefore, anticipates that portfolio management will decide which drug research initiatives to support or forego. It will help them take on initiatives that will be very valuable to the business and drop those that are just marginally valuable. The project manager and key stakeholders decide whether to move forward or abandon a project.

Before the new medicine is approved for submission, the Lifecycle Pharmaceutical scope will have three stages, which will make its operations more effective. Phase I is the project launch, during which the new medicine will be presented to the organization; little research and development will be conducted to see if the project is strategically appropriate for the organization and will provide positive outcomes at the project's conclusion. At this stage, a charter and a project team will be created. Phase II, which focuses on project definition and planning, includes creating a project schedule and ensuring every project component is understood and specified by everyone on the project team. The project's finance and other requirements will be resolved at this stage.

The project's strategy will be implemented during the third and final phase, known as project execution. It would be pointless if the company didn't press through with the project after determining that it was both strategically and financially advantageous. Any difficulties or worries will be brought up at this phase and reported to the stakeholders for assessment and approval before proceeding. As a result, there will be clear communication among the project's major players and plenty of opportunity for input without the project's timeline being extended. The drug research and development procedures will become more productive and less expensive to run with the help of project management.

The following are the skills that must be attained for the project to be completed:

· Align the organization's strategic goals with the business goals.

· Use clever portfolio management techniques.

· Lower the price of medicine development and research.

· Raise the value of the portfolio.

· Create and maintain a TPP for each project.

The project's parameters will encompass the development stages of four distinct types of medications. The four medications that fall under the purview of the project that Lifecycle Pharmaceuticals is presenting will be the only ones to which the project requirements will apply. All other medications will still go through the initial procedure even if they are not included in the scope of this study.

Lifecycle Pharmaceuticals will only select projects through portfolio management that are strategically appropriate for the company, offer significant value, and result in a successful execution consistent with the project's objectives and strategic business goals. By effectively fulfilling milestones and deliverables, the project team will adhere to the project charter, remain within budget, and successfully execute the project's end item on the schedule.

The project deliverable of Lifecycle Pharmaceuticals is a thorough report covering the four pharmaceuticals that will go through research and development phases to make sure they are strategically appropriate for the corporation. For stakeholders, the message will be pervasive, but it will also have the correct amount of information to give accurate information on each medicine. The following are some of the deliverables included in the thorough report:

· The project goals and the company strategy are in sync.

· Establish a go/no-go standard for every milestone.

· Less expensive medication development.

· Make the production process more efficient.

· Portfolio management implementation.

· Making wise choices on portfolio management.

· Create and maintain TPPs for each product.

· Develop new medications and enhance those identified.

When all the project's milestones occurred, deliverables that fell under its purview were successfully performed and met within the project's budget and time. When the productivity was effectively and efficiently handled, each of the four medications must undergo testing and FDA approval. The project is declared finished and acknowledged by management and stakeholders. Each project must meet the following criteria to be accepted: decreased drug development costs; improved portfolio management; and stakeholder assessment of whether the initiative strategically aligns with the organization.

Project Constraints

Any project element assumed to be accurate, actual, or specific without supporting evidence or demonstration is known as an assumption. It isn't easy to plan a project without considering some things. The trick is to recognize these assumptions and put protections in place so that the impact on project completion if any assumption turns out to be untrue, will be as little as possible. Every project assumption carries a potential risk; it's critical to remember that. Because of this, assumption analysis is an essential part of risk management planning, and each project manager (PM) should be aware of the correct methods for evaluating, communicating, and documenting assumptions.

Scope, budget, quality, and time are a few project limitations. These limitations will be communicated to ensure that the stakeholders are aware of the constraints that must be met for the project to be completed. This document specifies the scope, which cannot be modified without permission. Because a predetermined budget has been agreed upon for the project and may only be changed with consent, financing is restricted for the project's duration. At no stage will the quality of the finished items be compromised during the process. Quality may be expensive, specified in the project's scope, and there may be problems with compliance. The project's schedule is a constraint since it must successfully and on time complete each milestone to reach its intended deadline.

The following project assumptions are that there will be sufficient resources available throughout the project's life and that they will be attainable at the same time, that stakeholders will be interested in project improvements, that deliverables will be defined in the scope, that project objectives will be met at the project's conclusion, and that the project will be completed on time and within budget.

The pharmaceutical business is experiencing various issues due to the demand for medicines increasing in price. The rise in expenses may be linked to increased development and manufacturing expenditures, but portfolio management will be required to examine its processes. This project underwent a cost-benefit analysis, which showed that portfolio management had concluded that the precise distribution of resources during the drug development phases had resulted in maximum returns by addressing the primary expenditures associated with the pass rate of each medicine. It has been demonstrated that therapy with a 50% success rate will enter the market and provide a 90% return on investment, indicating that the advantages of creating this new treatment will ultimately surpass the expenditures associated with its creation.

Sponsor Acceptance

Approved by the Project Sponsor:

Date:

Reference

Bode-Greuel, K. M., & Nickisch, K. J. (2008). Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development–Commonalities and differences in portfolio management practice. Journal of Commercial Biotechnology, 14(4), 307-325.